Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Menactra Generic Name & Formulations
Legal Class
Rx
General Description
Neisseria meningitidis polysaccharides 4mcg each of Group A, C, Y, and W-135; per 0.5mL; (diphtheria toxoid conjugate); soln for IM inj; preservative-free.
How Supplied
Single-dose vials—5
Manufacturer
Menactra Indications
Indications
Meningitis immunization.
Menactra Dosage and Administration
Adults and Children
<9mos: not recommended. Give by IM inj only in deltoid region. Primary vaccination: 9–23mos: 0.5mL given as 2-dose series three months apart; 2–55yrs: 0.5mL once. Booster vaccination: 15–55yrs: may give a single (0.5mL) dose for those at continued risk, if at least 4yrs have elapsed since the prior dose.
Menactra Contraindications
Contraindications
Severe allergic reaction to any previous meningococcal capsular polysaccharide-, diphtheria toxoid- or CRM197-containing vaccine.
Menactra Boxed Warnings
Not Applicable
Menactra Warnings/Precautions
Warnings/Precautions
Have epinephrine inj (1:1000) available. History of Guillain-Barre syndrome. Immunosuppressed. Risk of syncope. Latex allergy. Adults >55yrs old. Pregnancy (Cat.C). Nursing mothers.
Menactra Pharmacokinetics
See Literature
Menactra Interactions
Interactions
Immunosuppressants (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, high-dose steroids) may get suboptimal response. Concomitant vaccines: see full labeling.
Menactra Adverse Reactions
Adverse Reactions
Inj site reactions, headache, fatigue, malaise, arthralgia, vomiting, diarrhea, anorexia, chills, fever, rash, irritability, drowsiness; children: also, abnormal crying.
Menactra Clinical Trials
See Literature
Menactra Note
Notes
To register pregnant patients or to report adverse events call (800) 822-2463. Refer to www.cdc.gov for ACIP guidelines on vaccinating acutely ill patients.
Menactra Patient Counseling
See Literature
Images
